In yesterday’s Wall Street session, Blueprint Medicines Corporation (NASDAQ:BPMC) shares traded at $54.30, down -15.34% from the previous session.
As of this writing, 19 analysts cover Blueprint Medicines Corporation (NASDAQ:BPMC). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $114.00 and a low of $42.00, we find $80.00. Given the previous closing price of $64.14, this indicates a potential upside of 24.73 percent. BPMC stock price is now -9.04% away from the 50-day moving average and 9.04% away from the 200-day moving average. The market capitalization of the company currently stands at $3.11B.
There are 4 analysts who have given it a hold rating, whereas 12 have given it a buy rating. Brokers who have rated the stock have averaged $74.65 as their price target over the next twelve months.
With the price target enhanced from $55 to $82, Wells Fargo Upgraded its rating from Equal Weight to Overweight for Blueprint Medicines Corporation (NASDAQ: BPMC).
In other news, Carter Percy H., CHIEF SCIENTIFIC OFFICER sold 2,307 shares of the company’s stock on Jun 05. The stock was sold for $120,102 at an average price of $52.06. Upon completion of the transaction, the CHIEF SCIENTIFIC OFFICER now directly owns 38,117 shares in the company, valued at $2.07 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 05, CHIEF MEDICAL OFFICER Hewes L. Becker sold 1,404 shares of the business’s stock. A total of $73,078 was realized by selling the stock at an average price of $52.05. This leaves the insider owning 36,878 shares of the company worth $2.0 million. Insiders disposed of 115,600 shares of company stock worth roughly $6.28 million over the past 1 year. A total of 1.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BPMC stock. A new stake in Blueprint Medicines Corporation shares was purchased by BAKER BROS. ADVISORS LP during the first quarter worth $18,118,000. JACOBS LEVY EQUITY MANAGEMENT, INC invested $6,888,000 in shares of BPMC during the first quarter. In the first quarter, SCHONFELD STRATEGIC ADVISORS LLC acquired a new stake in Blueprint Medicines Corporation valued at approximately $3,781,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in BPMC for approximately $2,245,000. HARBOR CAPITAL ADVISORS, INC. purchased a new stake in BPMC valued at around $1,322,000 in the second quarter.
Wednesday morning saw Blueprint Medicines Corporation (NASDAQ: BPMC) opened at $59.31. During the past 12 months, Blueprint Medicines Corporation has had a low of $37.82 and a high of $79.40. As of last week, the company has a debt-to-equity ratio of 0.34, a current ratio of 5.20, and a quick ratio of 5.10. The fifty day moving average price for BPMC is $59.69 and a two-hundred day moving average price translates $49.81 for the stock.
According to the Biotechnology Company, earnings per share came in at -$2.15, beating analysts’ expectations of -$2.67 by 0.52. This compares to -$1.79 EPS in the same period last year. The company reported revenue of $63.29 million for the quarter, compared to $62.73 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.89 percent. For the current quarter, analysts expect BPMC to generate $45.47M in revenue.
